期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 63, 期 4-5, 页码 324-330出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2011.01.013
关键词
Stem cells; Embryonic stem cells; Induced pluripotent stem cells; Regenerative therapies; Biomedical discovery
资金
- Alberta Heritage Foundation
- NIH [HL080111, HL094941]
- CIRM [RB1-01354]
- Laubisch and Cardiovascular Development Funds
The discovery of induced pluripotent stem cells (iPSC) has, in the short time since their discovery, revolutionized the field of stem cell biology. This technology allows the generation of a virtually unlimited supply of cells with pluripotent potential similar to that of embryonic stem cells (ESC). However, in contrast to ESC, iPSC are not subject to the same ethical concerns and can be easily generated from living individuals. For the first time, patient-specific iPSC can be generated and offer a supply of genetically identical cells that can be differentiated into all somatic cell types for potential use in regenerative therapies or drug screening and testing. As the techniques for generation of iPSC lines are constantly evolving, new uses for human iPSC are emerging from in-vitro disease modeling to high throughput drug discovery and screening. This technology promises to revolutionize the field of medicine and offers new hope for understanding and treatment of numerous diseases. (C) 2011 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据